Bank of New York Mellon
CUE icon

Bank of New York Mellon’s Cue Biopharma CUE Stock Holding History

Bank of New York Mellon’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,074
Closed -$174K – 4157
2024
Q1 		$174K Sell
3,074
-571
-16% -$40.3K ﹤0.01% 3967
2023
Q4 		$289K Buy
3,645
+211
+6% +$15.1K ﹤0.01% 3813
2023
Q3 		$237K Sell
3,434
-4
-0.1% -$391 ﹤0.01% 3903
2023
Q2 		$377K Buy
3,438
+2,728
+384% +$321K ﹤0.01% 3735
2023
Q1 		$76K Hold
710
– – ﹤0.01% 4117
2022
Q4 		$60.7K Sell
710
-1
-0.1% -$91 ﹤0.01% 4208
2022
Q3 		$48K Hold
711
– – ﹤0.01% 4330
2022
Q2 		$53K Sell
711
-2,928
-80% -$342K ﹤0.01% 4334
2022
Q1 		$533K Buy
3,639
+81
+2% +$17.2K ﹤0.01% 3668
2021
Q4 		$1.21M Sell
3,558
-13
-0.4% -$5.03K ﹤0.01% 3273
2021
Q3 		$1.56M Buy
3,571
+218
+7% +$76K ﹤0.01% 3139
2021
Q2 		$1.17M Sell
3,353
-314
-9% -$122K ﹤0.01% 3305
2021
Q1 		$1.34M Sell
3,667
-165
-4% -$67.9K ﹤0.01% 3166
2020
Q4 		$1.44M Buy
3,832
+121
+3% +$48.3K ﹤0.01% 3032
2020
Q3 		$1.68M Sell
3,711
-2
-0.1% -$1.15K ﹤0.01% 2765
2020
Q2 		$2.73M Buy
3,713
+1,232
+50% +$892K ﹤0.01% 2504
2020
Q1 		$1.06M Buy
2,481
+272
+12% +$132K ﹤0.01% 2941
2019
Q4 		$1.05M Buy
2,209
+339
+18% +$106K ﹤0.01% 3225
2019
Q3 		$473K Sell
1,870
-3
-0.2% -$721 ﹤0.01% 3565
2019
Q2 		$505K Buy
1,873
+5
+0.3% +$1.24K ﹤0.01% 3597
2019
Q1 		$433K Buy
1,868
+142
+8% +$27K ﹤0.01% 3615
2018
Q4 		$243K Buy
1,726
+243
+16% +$44.1K ﹤0.01% 3784
2018
Q3 		$403K Sell
1,483
-1
-0.1% -$289 ﹤0.01% 3732
2018
Q2 		$527K Buy
1,484
+741
+100% +$295K ﹤0.01% 3612
2018
Q1 		$313K Buy
+743
New +$339K ﹤0.01% 3781

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Bank of New York Mellon's CUE Position: Q2 2024 in Review

Bank of New York Mellon sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 3,074 shares — an estimated $174K sold.

Bank of New York Mellon first reported a position in CUE in Q1 2018 and held it in 25 quarters. The position peaked at $2.73M in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Bank of New York Mellon reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 3,074 Cue Biopharma shares in Q2 2024, an estimated $174K.
  • Bank of New York Mellon first reported a position in Cue Biopharma in Q1 2018 and held it in 25 quarters.
  • Bank of New York Mellon's Cue Biopharma position peaked at $2.73M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.